Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Markedly elevated GAD antibodies in SPS: effects of age and illness duration.

Literature DB >> 15596766

Markedly elevated GAD antibodies in SPS: effects of age and illness duration.

B B Murinson¹, M Butler, K Marfurt, S Gleason, P De Camilli, M Solimena.

Abstract

Five hundred seventy-six patients with suspected stiff-person syndrome (SPS) underwent immunocytochemistry (ICC). Of these, 286 underwent radioimmunoassay (RIA) for glutamic acid decarboxylase (GAD) antibodies; 116 were GAD antibody positive by one or both tests. Ninety-six percent of those positive by ICC had RIA values several standard deviations above normal. RIA did not correlate with age or illness duration. Marked elevations of RIA for GAD antibodies were characteristic of ICC-confirmed SPS, and modest elevations were not.

Entities: Gene Species

Mesh：

Substances：

Year: 2004 PMID： 15596766 DOI： 10.1212/01.wnl.0000145661.01675.a8

Source DB: PubMed Journal: Neurology ISSN： 0028-3878 Impact factor: 9.910

Keyword Cloud
Cited

15 in total

Review 1. GABA-based evaluation of neurologic conditions: MR spectroscopy.

Authors: L M Levy; A J Degnan
Journal: AJNR Am J Neuroradiol Date: 2012-01-19 Impact factor: 3.825

2. An uncommon paraneoplastic Ri-positive opsoclonus-myoclonus-like syndrome and stiff-person syndrome with elevated glutamate/GABA ratio in the cerebrospinal fluid after breast cancer.

Authors: A Thümen; A Moser
Journal: J Neurol Date: 2010-02-23 Impact factor: 4.849

3. Intravenous immunoglobulin in patients with anti-GAD antibody-associated neurological diseases and patients with inflammatory myopathies: effects on clinicopathological features and immunoregulatory genes.

Authors: Marinos C Dalakas
Journal: Clin Rev Allergy Immunol Date: 2005-12 Impact factor: 8.667

Review 4. Role of IVIg in autoimmune, neuroinflammatory and neurodegenerative disorders of the central nervous system: present and future prospects.

Authors: Marinos C Dalakas
Journal: J Neurol Date: 2006-09 Impact factor: 4.849

5. A case of glycine-receptor antibody-associated encephalomyelitis with rigidity and myoclonus (PERM): clinical course, treatment and CSF findings.

Authors: A Piotrowicz; A Thümen; M I Leite; A Vincent; A Moser
Journal: J Neurol Date: 2011-05-04 Impact factor: 4.849

6. The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies.

Authors: Marinos C Dalakas
Journal: J Neurol Date: 2005-05 Impact factor: 4.849

Markedly elevated GAD antibodies in SPS: effects of age and illness duration.

Review 1. GABA-based evaluation of neurologic conditions: MR spectroscopy.

2. An uncommon paraneoplastic Ri-positive opsoclonus-myoclonus-like syndrome and stiff-person syndrome with elevated glutamate/GABA ratio in the cerebrospinal fluid after breast cancer.

3. Intravenous immunoglobulin in patients with anti-GAD antibody-associated neurological diseases and patients with inflammatory myopathies: effects on clinicopathological features and immunoregulatory genes.

Review 4. Role of IVIg in autoimmune, neuroinflammatory and neurodegenerative disorders of the central nervous system: present and future prospects.

5. A case of glycine-receptor antibody-associated encephalomyelitis with rigidity and myoclonus (PERM): clinical course, treatment and CSF findings.

6. The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies.

Review 7. Intravenous immunoglobulin therapy in paraneoplastic neurological syndromes.

8. Stiff person syndrome: advances in pathogenesis and therapeutic interventions.

Review 9. Advances in the pathogenesis and treatment of patients with stiff person syndrome.

10. Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease.